Predictors of responsiveness to ketamine: An updated systematic review of neuroimaging findings.
Journal of Affective Disorders July 15, 2026 Iman Kiani, Giulia Cattarinussi, Fabio Sambataro et al.
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant portion of patients experiencing treatment-resistant depression (TRD). Ketamine, a rapid-acting antidepressant, has shown promise in alleviating symptoms of TRD and suicidality, but variability in treatment response remains a challenge. Identifying neuroimaging biomarkers that predict responsiveness...
DOI: 10.1016/j.jad.2026.121521 (opens in new tab)
Full text (opens in new tab)
Ketamine
Major depressive disorder
Neuroimaging
Suicidality